Publications in collaboration with researchers from Duke University (2)

2020

  1. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    Leukemia, Vol. 34, Núm. 12, pp. 3298-3309

2011

  1. Reply to A. Gratwohl

    Journal of Clinical Oncology